![AOS - A.O. Smith Corp - Stock Price Chart]() |
| Market Cap | 7.72B | EPS (TTM) | 3.75 |
| P/E | 14.94 | EPS this Y | -1.70% |
| Forward P/E | 13.46 | EPS next Y | 9.98% |
| PEG | 2.66 | EPS past 5Y | 12.66% |
| P/S | 2.03 | EPS next 5Y | 5.05% |
| P/B | 4.11 | EPS Q/Q | -10.36% |
| Dividend | 2.59% | Sales Q/Q | -1.90% |
| Insider Own | 19.92% | Inst Own | 84.49% |
| Insider Trans | -0.01% | Inst Trans | 1.73% |
| Short Float | 7.26% | Earnings | Apr 30/b |
| Analyst Recom | 2.62 | Target Price | 70.80 |
| Avg Volume | 1.54M | 52W Range | 56.77 - 81.86 |
|
|
| May-15-26 | Downgrade |
JP Morgan |
Neutral → Underweight |
$60 |
|
|
|
A. O. Smith Corp. manufactures residential and commercial gas and electric water heaters, boilers, tanks, and water treatment products. It operates through the North America and Rest of World segments. The North America segment manufactures and markets comprehensive lines of residential and commercial gas and electric water heaters, boilers, and tanks. The Rest of World segment markets water treatment products in China, Europe, and India. The company was founded by Charles Jeremiah Smith in 1874 and is headquartered in Milwaukee, WI. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| DARRELL SCHUH | Officer | Mar 04 '26 | Proposed Sale | 74.39 | 1,104 | 82,126 | | Mar 04 04:14 PM | | Schuh Darrell W. | SVP; President & GM Lochinvar | Mar 04 '26 | Sale | 74.39 | 1,104 | 82,126 | 2,201 | Mar 04 03:30 PM | | Wheeler Kevin J. | Executive Chairman | Feb 13 '26 | Option Exercise | 0.00 | 36,045 | 0 | 136,692 | Feb 17 02:31 PM | | STERN JAMES F | Exec VP, Corp Dev, Strat & Sec | Feb 13 '26 | Option Exercise | 0.00 | 6,850 | 0 | 103,134 | Feb 17 02:29 PM | | Schuh Darrell W. | SVP; President & GM Lochinvar | Feb 13 '26 | Option Exercise | 0.00 | 1,460 | 0 | 3,651 | Feb 17 02:25 PM |
|
|
 |
![AARD - Aardvark Therapeutics Inc - Stock Price Chart]() |
| Market Cap | 99.70M | EPS (TTM) | -3.21 |
| P/E | - | EPS this Y | -22.61% |
| Forward P/E | - | EPS next Y | 9.20% |
| PEG | - | EPS past 5Y | - |
| P/S | - | EPS next 5Y | 0.03% |
| P/B | 1.15 | EPS Q/Q | -130.51% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 44.68% | Inst Own | 29.72% |
| Insider Trans | 0.10% | Inst Trans | 1.54% |
| Short Float | 10.06% | Earnings | May 07/b |
| Analyst Recom | 2.25 | Target Price | 17.90 |
| Avg Volume | 282.63K | 52W Range | 3.35 - 17.94 |
|
|
| May-15-26 | Downgrade |
Morgan Stanley |
Equal-Weight → Underweight |
$3 |
|
|
|
Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Sun Nelson | Chief Financial Officer | Dec 11 '25 | Buy | 14.40 | 3,000 | 43,200 | 108,484 | Dec 12 08:30 PM | | Lee Tien-Li | Chief Executive Officer | Dec 11 '25 | Buy | 14.48 | 7,000 | 101,395 | 1,551,613 | Dec 12 08:30 PM | | Lee Tien-Li | Chief Executive Officer | Oct 15 '25 | Option Exercise | 4.24 | 1,229 | 5,211 | 1,544,613 | Oct 16 06:14 PM | | Jones Bryan | Chief Operating Officer | Oct 15 '25 | Option Exercise | 4.24 | 1,250 | 5,300 | 1,250 | Oct 16 06:12 PM | | Lee Tien-Li | Chief Executive Officer | Sep 15 '25 | Buy | 9.66 | 10,000 | 96,624 | 1,543,384 | Sep 16 06:15 AM |
|
|
 |
![AEG - Aegon Ltd - Stock Price Chart]() |
| Market Cap | 12.62B | EPS (TTM) | 0.71 |
| P/E | 11.88 | EPS this Y | 58.29% |
| Forward P/E | 7.73 | EPS next Y | -1.18% |
| PEG | 0.38 | EPS past 5Y | 95.22% |
| P/S | 0.39 | EPS next 5Y | 20.56% |
| P/B | 1.43 | EPS Q/Q | -82.58% |
| Dividend | 6.06% | Sales Q/Q | -32.54% |
| Insider Own | 0.00% | Inst Own | 10.80% |
| Insider Trans | - | Inst Trans | -2.09% |
| Short Float | 0.17% | Earnings | Feb 19/b |
| Analyst Recom | 1.93 | Target Price | 8.84 |
| Avg Volume | 5.83M | 52W Range | 6.64 - 8.48 |
|
|
| May-15-26 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
|
|
Aegon Ltd. is an international financial services company, which engages in the provision of investment, protection, and retirement solutions. It operates through the following segments: Americas, The Netherlands, United Kingdom, International, Asset Management, and Holding and Other Activities. The Americas segment covers business units in the United States and Brazil, including any of the units' activities located outside these countries. The Netherlands segment covers businesses activities from Aegon the Netherlands. The United Kingdom segment involves existing business and digital solutions. The International segment encompasses Hong Kong, Singapore, China, India, Indonesia, Hungary, Poland, Turkey, Romania, Spain, and Portugal. The Asset Management segment consists of Aegon Asset Management Global Platforms and strategic partnerships. The Holding and Other activities refers to financing, employee, and other administrative expenses of holding companies. The company was founded in 1844 and is headquartered in The Hague, the Netherlands. |
|
|  |
![ALLE - Allegion plc - Stock Price Chart]() |
| Market Cap | 10.80B | EPS (TTM) | 7.32 |
| P/E | 17.16 | EPS this Y | 7.69% |
| Forward P/E | 13.16 | EPS next Y | 8.92% |
| PEG | 1.54 | EPS past 5Y | 16.90% |
| P/S | 2.60 | EPS next 5Y | 8.54% |
| P/B | 5.14 | EPS Q/Q | -6.70% |
| Dividend | 1.70% | Sales Q/Q | 9.74% |
| Insider Own | 0.42% | Inst Own | 102.98% |
| Insider Trans | -0.49% | Inst Trans | 1.08% |
| Short Float | 4.17% | Earnings | Apr 28/b |
| Analyst Recom | 2.25 | Target Price | 165.55 |
| Avg Volume | 1.01M | 52W Range | 130.07 - 183.11 |
|
|
| May-15-26 | Downgrade |
JP Morgan |
Overweight → Neutral |
$150 |
|
|
|
Allegion Plc engages in the provision of security products and solutions that keep people safe, secure, and productive. It operates through the Allegion Americas and Allegion International segments. The Allegion Americas segment offers security products, services, and solutions throughout North America. The Allegion International segment refers to security products, services, and solutions primarily throughout Europe, Asia and Oceania. The company was founded on May 9, 2013 and is headquartered in Dublin, Ireland. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Martens Robert C. | SVP-Chief Innovation & Design | May 07 '26 | Sale | 137.15 | 3,993 | 547,640 | 8,570 | May 11 12:18 PM | | Robert Martens | Officer | May 07 '26 | Proposed Sale | 137.15 | 3,993 | 547,658 | | May 07 04:26 PM | | MAIN SUE | Director | Mar 11 '26 | Buy | 149.61 | 2,000 | 299,215 | 2,000 | Mar 12 02:56 PM | | MIZELL STEVEN | Director | Feb 19 '26 | Sale | 161.51 | 1,000 | 161,510 | 4,915 | Feb 20 02:08 PM | | MIZELL STEVEN | Director | Feb 18 '26 | Sale | 163.79 | 400 | 65,516 | 5,915 | Feb 20 02:08 PM |
|
|
 |
![ALMS - Alumis Inc - Stock Price Chart]() |
| Market Cap | 2.91B | EPS (TTM) | -1.92 |
| P/E | - | EPS this Y | 0.13% |
| Forward P/E | - | EPS next Y | 4.28% |
| PEG | - | EPS past 5Y | - |
| P/S | 346.32 | EPS next 5Y | 13.32% |
| P/B | 5.13 | EPS Q/Q | 59.19% |
| Dividend | - | Sales Q/Q | -89.99% |
| Insider Own | 34.97% | Inst Own | 53.55% |
| Insider Trans | 12.18% | Inst Trans | 5.02% |
| Short Float | 13.65% | Earnings | May 14/a |
| Analyst Recom | 1.27 | Target Price | 39.90 |
| Avg Volume | 1.36M | 52W Range | 2.76 - 30.60 |
|
|
| May-15-26 | Downgrade |
H.C. Wainwright |
Buy → Neutral |
$25 |
|
|
|
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| AKKARAJU SRINIVAS | Director | Jan 09 '26 | Buy | 17.00 | 588,235 | 9,999,995 | 1,853,488 | Jan 13 06:20 PM | | Foresite Labs, LLC | 10% Owner | Jan 08 '26 | Buy | 17.00 | 411,764 | 6,999,988 | 5,702,536 | Jan 12 09:59 PM | | Foresite Capital Management VI | 10% Owner | Jan 08 '26 | Buy | 17.00 | 411,764 | 6,999,988 | 5,702,536 | Jan 12 09:58 PM | | Tananbaum James B. | Director | Jan 08 '26 | Buy | 17.00 | 411,764 | 6,999,988 | 5,702,536 | Jan 12 09:58 PM | | AKKARAJU SRINIVAS | Director | Dec 05 '25 | Buy | 9.84 | 186,377 | 1,833,760 | 1,265,253 | Dec 09 07:13 PM |
|
|
|  |
![CCAP - Crescent Capital BDC Inc - Stock Price Chart]() |
| Market Cap | 410.10M | EPS (TTM) | 0.41 |
| P/E | 27.41 | EPS this Y | -12.71% |
| Forward P/E | 7.38 | EPS next Y | -4.52% |
| PEG | - | EPS past 5Y | -13.95% |
| P/S | 2.80 | EPS next 5Y | -6.07% |
| P/B | 0.61 | EPS Q/Q | -498.96% |
| Dividend | 13.68% | Sales Q/Q | -27.42% |
| Insider Own | 14.75% | Inst Own | 55.68% |
| Insider Trans | 0.04% | Inst Trans | - |
| Short Float | 1.66% | Earnings | May 13/a |
| Analyst Recom | 1.71 | Target Price | 14.36 |
| Avg Volume | 207.32K | 52W Range | 11.80 - 16.29 |
|
|
| May-15-26 | Upgrade |
B. Riley Securities |
Neutral → Buy |
$13.50 |
| May-15-26 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
|
|
Crescent Capital BDC, Inc. is a traded business development company, which engages in investing in middle market companies located in the United States. The fund focuses on companies operating across a broad range of sectors. It provides financing in the form of secured debt including first lien, second lien debt, unsecured debt, mezzanine subordinated debt, and equity securities for buyout transactions. The firm acquires controlling interest. The company was founded on February 5, 2015 and is headquartered in Los Angeles, CA. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Lombard Gerhard | Chief Financial Officer | Nov 17 '25 | Buy | 13.34 | 2,000 | 26,683 | 34,284 | Nov 18 04:11 PM | | Bouek Kirill | Controller | Aug 28 '25 | Buy | 15.67 | 200 | 3,133 | 1,057 | Aug 29 04:17 PM | | Barrios Raymond | Managing Director | Aug 25 '25 | Buy | 15.63 | 3,245 | 50,713 | 19,177 | Aug 26 05:22 PM | | UFCW-Northern California Emplo | 10% Owner | May 29 '25 | Sale | 15.31 | 303,980 | 4,653,934 | 3,902,095 | Aug 18 05:39 PM | | UFCW-Northern California Emplo | 10% Owner | Jun 03 '25 | Sale | 14.90 | 109,429 | 1,630,492 | 3,738,095 | Aug 18 05:39 PM |
|
|
 |
![DOCS - Doximity Inc - Stock Price Chart]() |
| Market Cap | 3.50B | EPS (TTM) | 0.98 |
| P/E | 19.29 | EPS this Y | -5.73% |
| Forward P/E | 11.91 | EPS next Y | 11.16% |
| PEG | 1.70 | EPS past 5Y | 52.56% |
| P/S | 5.43 | EPS next 5Y | 6.99% |
| P/B | 3.58 | EPS Q/Q | -67.50% |
| Dividend | - | Sales Q/Q | 5.12% |
| Insider Own | 29.77% | Inst Own | 67.87% |
| Insider Trans | -0.07% | Inst Trans | 1.38% |
| Short Float | 13.10% | Earnings | May 13/a |
| Analyst Recom | 2.16 | Target Price | 24.92 |
| Avg Volume | 3.45M | 52W Range | 17.15 - 76.51 |
|
|
| May-15-26 | Downgrade |
Barclays |
Overweight → Equal Weight |
$20 |
|
|
May-15-26 09:45AM
|
Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls
(The Fly) |
|
May-14-26 02:07PM
|
Why Wall Street is turning cautious on Doximity despite AI ambitions?
(Investing.com) |
|
10:09AM
|
Doximity, 'LinkedIn For Doctors,' Hits A Record Low On AI Growing Pains
(Investor's Business Daily) |
|
09:51AM
|
Stocks to Watch: Cisco, Cerebras, Doximity, Klarna
(The Wall Street Journal) |
|
09:45AM
|
Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls
(The Fly) |
|
08:07AM
|
5 Things to Know Before the Stock Market Opens
(Investopedia) |
|
05:58AM
|
These Stocks Are Today's Movers: Cisco, Micron, Nvidia, Fervo, Doximity, StubHub, and More
(Barrons.com) |
|
05:21AM
|
Cisco System surges after results, and other early market movers
(MarketWatch) |
|
01:00AM
|
Doximity Inc (DOCS) Q4 2026 Earnings Call Highlights: Record Free Cash Flow and AI Integration ...
(GuruFocus.com) |
|
May-13-26 05:08PM
|
Doximity Stock Plummets. A Weak Revenue Outlook Is Weighing on the Telehealth Company.
(Barrons.com) |
|
Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Sitaram Siddharth | Interim PFO and PAO | May 11 '26 | Sale | 25.77 | 2,309 | 59,503 | 89,396 | May 13 04:10 PM | | SIDDHARTH SITARAM | Officer | May 11 '26 | Proposed Sale | 25.77 | 2,309 | 59,503 | | May 11 04:01 PM | | Wampler Kira Scherer | Director | May 07 '26 | Sale | 26.06 | 9,000 | 234,540 | 19,839 | May 08 06:00 PM | | KIRA WAMPLER | Director | May 07 '26 | Proposed Sale | 26.06 | 9,000 | 234,540 | | May 07 04:03 PM | | Sitaram Siddharth | Interim PFO and PAO | Apr 10 '26 | Sale | 21.09 | 2,427 | 51,185 | 86,705 | Apr 14 05:56 PM |
|
|
|  |
![FRMI - Fermi Inc - Stock Price Chart]() |
| Market Cap | 4.15B | EPS (TTM) | - |
| P/E | - | EPS this Y | 106.86% |
| Forward P/E | 5.66 | EPS next Y | 1513.11% |
| PEG | - | EPS past 5Y | - |
| P/S | - | EPS next 5Y | - |
| P/B | 3.82 | EPS Q/Q | - |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 61.48% | Inst Own | 8.18% |
| Insider Trans | -3.31% | Inst Trans | 132.29% |
| Short Float | 14.82% | Earnings | May 14/b |
| Analyst Recom | 1.44 | Target Price | 18.78 |
| Avg Volume | 14.12M | 52W Range | 4.47 - 36.99 |
|
|
| May-15-26 | Downgrade |
Evercore ISI |
Outperform → In-line |
$11 |
|
|
|
Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Hamilton Charles Lynn | Chief Site Development Officer | Apr 08 '26 | Sale | 4.91 | 375,950 | 1,845,914 | 5,924,050 | Apr 10 07:38 PM | | Hamilton Charles Lynn | Chief Site Development Officer | Apr 09 '26 | Sale | 4.58 | 398,140 | 1,823,481 | 5,525,910 | Apr 10 07:38 PM | | Ortiz Blanes Jacobo | Chief Operating Officer | Apr 08 '26 | Sale | 4.91 | 403,545 | 1,981,406 | 5,896,455 | Apr 10 07:38 PM | | Ortiz Blanes Jacobo | Chief Operating Officer | Apr 09 '26 | Sale | 4.58 | 427,363 | 1,957,323 | 5,469,092 | Apr 10 07:38 PM | | Everson Miles E. | Chief Financial Officer | Apr 08 '26 | Sale | 4.91 | 403,205 | 1,979,737 | 10,396,795 | Apr 10 07:37 PM |
|
|
 |
![GAMB - Gambling.com Group Ltd - Stock Price Chart]() |
| Market Cap | 84.23M | EPS (TTM) | -1.28 |
| P/E | - | EPS this Y | 140.67% |
| Forward P/E | 3.48 | EPS next Y | 82.16% |
| PEG | - | EPS past 5Y | - |
| P/S | 0.51 | EPS next 5Y | - |
| P/B | 0.79 | EPS Q/Q | -110.77% |
| Dividend | - | Sales Q/Q | -0.48% |
| Insider Own | 41.17% | Inst Own | 38.86% |
| Insider Trans | 0.06% | Inst Trans | -18.60% |
| Short Float | 8.75% | Earnings | May 14/a |
| Analyst Recom | 1.44 | Target Price | 5.88 |
| Avg Volume | 716.66K | 52W Range | 3.51 - 14.95 |
|
|
| May-15-26 | Downgrade |
The Benchmark Company |
Buy → Speculative Buy |
$4 |
|
|
|
Gambling.com Group Ltd is a marketing company, which engages in the provision of digital marketing services for the online gambling industry. It focuses on iGaming and sports betting. The company was founded by Charles Gillespie and Kevin McCrystle on July 26, 2006 and is headquartered in St. Helier, the United Kingdom. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Monaghan Ellen | SVP People | Apr 01 '26 | Option Exercise | 3.72 | 1,175 | 4,371 | 2,815 | Apr 24 03:36 PM | | Mark Martin Elias | CFO | Apr 15 '26 | Buy | 3.24 | 3,860 | 12,506 | 803,256 | Apr 22 02:23 PM | | McCrystle Kevin Ross | COO | Apr 15 '26 | Buy | 3.24 | 738 | 2,391 | 1,001,885 | Apr 22 02:21 PM | | Gillespie Charles | CEO | Apr 15 '26 | Buy | 3.24 | 3,860 | 12,506 | 226,641 | Apr 22 02:20 PM | | McCrystle Kevin Ross | COO | Apr 06 '26 | Option Exercise | 3.83 | 10,011 | 38,342 | 1,001,147 | Apr 08 11:20 AM |
|
|
 |
![JSPR - Jasper Therapeutics Inc - Stock Price Chart]() |
| Market Cap | 23.80M | EPS (TTM) | -3.23 |
| P/E | - | EPS this Y | 67.64% |
| Forward P/E | - | EPS next Y | -16.83% |
| PEG | - | EPS past 5Y | 48.97% |
| P/S | - | EPS next 5Y | 40.56% |
| P/B | 7.00 | EPS Q/Q | 97.10% |
| Dividend | - | Sales Q/Q | - |
| Insider Own | 13.62% | Inst Own | 52.31% |
| Insider Trans | 0.00% | Inst Trans | -13.47% |
| Short Float | 11.25% | Earnings | May 14/a |
| Analyst Recom | 2.00 | Target Price | 9.08 |
| Avg Volume | 410.83K | 52W Range | 0.62 - 7.19 |
|
|
| May-15-26 | Downgrade |
TD Cowen |
Buy → Hold |
|
|
|
|
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| WIGGANS THOMAS G | Director | Sep 22 '25 | Buy | 2.43 | 41,000 | 99,630 | 41,000 | Sep 24 04:01 PM | | Lucas Svetlana | Director | Sep 22 '25 | Buy | 2.43 | 20,000 | 48,600 | 20,000 | Sep 24 04:01 PM | | MARTELL RON | President and CEO | Sep 22 '25 | Buy | 2.43 | 41,000 | 99,630 | 74,118 | Sep 24 04:01 PM | | Shizuru Judith Anne | Director | Sep 22 '25 | Buy | 2.43 | 41,000 | 99,630 | 156,901 | Sep 24 04:01 PM |
|
|
|